Acute Leukemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ACT073 MIFTS: 58	Acute Leukemia Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Acute Leukemia

MalaCards integrated aliases for Acute Leukemia:

Name: Acute Leukemia ¹¹ ²⁸ ⁵³ ¹⁴ ³⁶ ¹⁶ ⁷¹ ⁷⁵

Stem Cell Leukaemia ¹¹ ³³

Acute Leukaemia of Unspecified Cell Type Without Mention of Remission ³³

Acute Undifferentiated Leukemia ⁷¹

Undifferentiated Leukaemia ³³

Undifferentiated Leukemia ⁷¹

Blast Cell Leukaemia ³³

Stem Cell Leukemia ¹¹

Blastic Leukaemia ³³

Acute Leukemias ¹⁴

Blast Leukaemia ³³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Blood diseases Immune diseases Bone diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Malignant haematopoietic neoplasms without further specification

Acute leukaemia, not elsewhere classified

External Ids:

Disease Ontology ¹¹ DOID:12603

ICD9CM ³⁴ 208.0

NCIt ⁴⁹ C9300

SNOMED-CT ⁶⁸ 24072005

EFO ¹⁶ EFO_1000068

ICD11 ³³ 962107653

UMLS ⁷¹ C0085669 C0280141 C1378511

Sources

Summaries for Acute Leukemia

Disease Ontology: ¹¹ A lymphoid leukemia that occurs when a hematopoietic stem cell undergoes malignant transformation into a primitive, undifferentiated cell with abnormal longevity producing large numbers of white blood cells to be produced and enter the blood stream.

MalaCards based summary: Acute Leukemia, also known as stem cell leukaemia, is related to acute biphenotypic leukemia and leukemia, acute lymphoblastic. An important gene associated with Acute Leukemia is KMT2A (Lysine Methyltransferase 2A), and among its related pathways/superpathways are Nervous system development and PI3K-Akt signaling pathway. The drugs Busulfan and Rasburicase have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, myeloid and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Reduced mammosphere formation

Wikipedia: ⁷⁵ Acute leukemia or acute leukaemia is a family of serious medical conditions relating to an original... more...

Sources

Related Diseases for Acute Leukemia

Diseases in the Leukemia family:

Chronic Leukemia	Acute Leukemia
Subacute Leukemia

Diseases related to Acute Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1047)

#	Related Disease	Score	Top Affiliating Genes
1	acute biphenotypic leukemia	33.4	PAX5 KMT2A KIT FLT3 ETV6 DNTT
2	leukemia, acute lymphoblastic	32.7	WT1 TCF3 RUNX1 PBX1 PAX5 MTHFR
3	leukemia	32.6	WT1 TCF3 STMN1 RUNX1 PBX1 MTHFR
4	leukemia, acute myeloid	32.6	WT1 TCF3 RUNX1 PBX1 PAX5 KRAS
5	mixed phenotype acute leukemia with t	32.5	KMT2A FLT3
6	mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2)	32.4	KMT2A FLT3
7	acute myeloblastic leukemia with maturation	32.4	KIT FLT3
8	mixed phenotype acute leukemia, t/myeloid	32.3	KMT2A FLT3
9	acute megakaryocytic leukemia	32.3	RUNX1 KMT2A KIT JAK2 FLT3 CEBPA
10	chronic leukemia	32.3	WT1 KIT JAK2 FLT3 ETV6
11	myelodysplastic syndrome	32.3	WT1 RUNX1 KRAS KMT2A KIT JAK2
12	acute myelomonocytic leukemia	32.3	RUNX1 KMT2A KIT FLT3 ETV6 DNTT
13	lymphoblastic lymphoma	32.2	PAX5 KRAS KMT2A DNTT
14	acute promyelocytic leukemia	32.2	WT1 RUNX1 KRAS KMT2A KIT FLT3
15	precursor t-cell acute lymphoblastic leukemia	31.9	KMT2A FLT3 ETV6 DNTT
16	neutropenia	31.8	KRAS JAK2 FLT3 CSF3 CEBPA
17	myeloid leukemia	31.8	WT1 RUNX1 KMT2A KIT JAK2 FLT3
18	leukemia, chronic myeloid	31.7	WT1 RUNX1 KRAS KMT2A KIT JAK2
19	b-lymphoblastic leukemia/lymphoma	31.7	TCF3 PBX1 PAX5 KMT2A KIT FLT3
20	down syndrome	31.7	RUNX1 MTHFR KMT2A JAK2 FLT3 ETV6
21	childhood acute lymphocytic leukemia	31.6	RUNX1 MTHFR KMT2A GSTM1 FLT3 ETV6
22	hematologic cancer	31.6	WT1 RUNX1 PAX5 KMT2A KIT JAK2
23	childhood leukemia	31.6	WT1 TCF3 PBX1 KMT2A KIT FLT3
24	pancytopenia	31.6	RUNX1 KMT2A KIT FLT3 CSF3
25	deficiency anemia	31.5	KIT JAK2 GSTM1 FLT3 CSF3
26	myeloproliferative neoplasm	31.4	RUNX1 KMT2A KIT JAK2 FLT3 ETV6
27	monocytic leukemia	31.4	RUNX1 KMT2A CSF3 CREBBP AFF1
28	myeloma, multiple	31.4	TCF3 PAX5 KRAS JAK2 FLT3 CSF3
29	lymphoma, non-hodgkin, familial	31.4	PAX5 KMT2A JAK2 FLT3 ETV6 DNTT
30	myeloid sarcoma	31.4	KMT2A KIT FLT3 DNTT
31	myelofibrosis	31.4	WT1 RUNX1 KIT JAK2 FLT3 ETV6
32	acute erythroid leukemia	31.3	KIT JAK2 FLT3 CEBPA
33	thrombocytopenia	31.3	RUNX1 PAX5 MTHFR KIT JAK2 FLT3
34	leukemia, acute monocytic	31.3	KMT2A FLT3 CREBBP
35	wilms tumor 1	31.3	WT1 KRAS KIT FLT3
36	burkitt lymphoma	31.3	TCF3 PAX5 DNTT CSF3
37	polycythemia vera	31.3	KIT JAK2 ETV6 CSF3
38	leukemia, chronic lymphocytic	31.2	PAX5 KRAS KMT2A KIT JAK2 FLT3
39	adult acute lymphocytic leukemia	31.2	TCF3 PBX1 PAX5 MTHFR KMT2A ETV6
40	essential thrombocythemia	31.1	KIT JAK2 FLT3 ETV6 CSF3
41	exanthem	31.1	KRAS KIT CSF3
42	childhood acute myeloid leukemia	31.0	WT1 KMT2A KIT FLT3 CEBPA
43	chronic myelomonocytic leukemia	31.0	RUNX1 KRAS KIT JAK2 FLT3 ETV6
44	central nervous system leukemia	31.0	PBX1 KMT2A ETV6 AFF1
45	mastocytosis	30.8	KIT JAK2 FLT3
46	myeloproliferative syndrome, transient	30.8	KMT2A KIT FLT3
47	blood platelet disease	30.8	RUNX1 KIT JAK2 FLT3 CSF3
48	neutrophilia, hereditary	30.7	JAK2 FLT3 CSF3
49	severe congenital neutropenia	30.6	RUNX1 JAK2 CSF3 CEBPA
50	medulloblastoma	30.6	STMN1 PAX5 KIT JAK2 CSF3 CREBBP

Comorbidity relations with Acute Leukemia via Phenotypic Disease Network (PDN):

Deficiency Anemia

Neutropenia

Graphical network of the top 20 diseases related to Acute Leukemia:

Sources

Symptoms & Phenotypes for Acute Leukemia

GenomeRNAi Phenotypes related to Acute Leukemia according to GeneCards Suite gene sharing:

²⁵ (show all 29)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-100	10.29	WT1
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-115	10.29	FLT3
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-116	10.29	FLT3
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	10.29	KRAS
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-122	10.29	WT1
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-123	10.29	DNTT
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-138	10.29	DNTT
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-145	10.29	DNTT WT1
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	10.29	DNTT
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-152	10.29	WT1
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	10.29	DNTT
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-16	10.29	DNTT
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-180	10.29	FLT3
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-182	10.29	DNTT
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	10.29	WT1
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-22	10.29	KRAS
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-25	10.29	FLT3
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-30	10.29	WT1
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	10.29	WT1
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	10.29	WT1
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-48	10.29	CEBPA
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	10.29	KRAS
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-70	10.29	FLT3
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-72	10.29	CEBPA
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	10.29	DNTT
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	10.29	WT1
27	no effect	GR00402-S-1	10.21	AFF1 BAALC CEBPA CREBBP CSF3 DNTT
28	no effect	GR00402-S-2	10.21	AFF1 BAALC CEBPA CREBBP CSF3 DNTT
29	Reduced mammosphere formation	GR00396-S	9.56	CEBPA CSF3 ETV6 GSTM1 KMT2A KRAS

MGI Mouse Phenotypes related to Acute Leukemia:

⁴⁵ (show all 23)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.48	CEBPA CREBBP DNTT ETV6 FLT3 GSTM1
2	normal	MP:0002873	10.45	CEBPA CREBBP DNTT ETV6 JAK2 KIT
3	nervous system	MP:0003631	10.4	AFF1 CREBBP GSTM1 JAK2 KIT KMT2A
4	growth/size/body region	MP:0005378	10.4	AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
5	neoplasm	MP:0002006	10.39	CEBPA CREBBP ETV6 FLT3 JAK2 KIT
6	liver/biliary system	MP:0005370	10.35	CEBPA CREBBP ETV6 JAK2 KIT KMT2A
7	no phenotypic analysis	MP:0003012	10.34	AFF1 CEBPA ETV6 FLT3 KIT KMT2A
8	cellular	MP:0005384	10.32	CEBPA CREBBP ETV6 FLT3 GSTM1 JAK2
9	immune system	MP:0005387	10.31	AFF1 CEBPA CREBBP CSF3 DNTT ETV6
10	endocrine/exocrine gland	MP:0005379	10.29	AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
11	renal/urinary system	MP:0005367	10.24	CEBPA CSF3 ETV6 KIT KMT2A KRAS
12	behavior/neurological	MP:0005386	10.21	AFF1 CEBPA CREBBP DNTT GSTM1 JAK2
13	cardiovascular system	MP:0005385	10.2	CEBPA CREBBP ETV6 JAK2 KIT KMT2A
14	embryo	MP:0005380	10.19	CREBBP ETV6 JAK2 KIT KMT2A KRAS
15	muscle	MP:0005369	10.18	CEBPA CREBBP KIT KMT2A KRAS PBX1
16	limbs/digits/tail	MP:0005371	10.1	CREBBP KIT KMT2A KRAS MTHFR PBX1
17	hematopoietic system	MP:0005397	10.06	AFF1 CEBPA CREBBP CSF3 DNTT ETV6
18	reproductive system	MP:0005389	10.02	AFF1 CEBPA JAK2 KIT KMT2A KRAS
19	hearing/vestibular/ear	MP:0005377	10.01	GSTM1 KIT KMT2A KRAS PAX5 PBX1
20	skeleton	MP:0005390	10	CREBBP ETV6 FLT3 JAK2 KIT KMT2A
21	respiratory system	MP:0005388	9.97	CEBPA CREBBP JAK2 KIT KRAS PBX1
22	mortality/aging	MP:0010768	9.83	AFF1 CEBPA CREBBP ETV6 FLT3 JAK2
23	integument	MP:0010771	9.36	CEBPA CREBBP CSF3 ETV6 JAK2 KIT

Sources

Drugs & Therapeutics for Acute Leukemia

Drugs for Acute Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 347)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Busulfan

Approved, Investigational

Phase 4

55-98-1

2478

Rasburicase

Approved, Investigational

Phase 4

134774-45-1

Ceftazidime

Approved

Phase 4

78439-06-2, 72558-82-8

5481173

Cefepime

Approved, Investigational

Phase 4

88040-23-7

5479537

Uric acid

Investigational

Phase 4

69-93-2

1175

Imatinib Mesylate

Phase 4

220127-57-1

HH-GV-678

Phase 4

Oprelvekin

Approved, Investigational

Phase 2, Phase 3

145941-26-0

Amphotericin B

Approved, Investigational

Phase 3

1397-89-3

5280965

Thiotepa

Approved, Investigational

Phase 3

52-24-4

5453

Coenzyme M

Approved, Investigational

Phase 3

3375-50-6

598 23662354

Clove

Approved

Phase 2, Phase 3

84961-50-2

Levofloxacin

Approved, Investigational

Phase 3

100986-85-4

149096

Ofloxacin

Approved

Phase 3

82419-36-1

4583

Sodium citrate

Approved, Investigational

Phase 3

68-04-2

23431961

Nalbuphine

Approved

Phase 3

20594-83-6

5311304

Morphine

Approved, Investigational

Phase 3

57-27-2

5288826

Rituximab

Approved

Phase 3

174722-31-7

Decitabine

Approved, Investigational

Phase 3

2353-33-5

451668

Lomustine

Approved, Investigational

Phase 2, Phase 3

13010-47-4

3950

Tioguanine

Approved

Phase 3

154-42-7

2723601

Hydroxyurea

Approved

Phase 2, Phase 3

127-07-1

3657

Inotuzumab ozogamicin

Approved, Investigational

Phase 3

635715-01-4

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3

50-02-2

3003 5743

Ichthammol

Approved

Phase 3

8029-68-3

Levoleucovorin

Approved, Experimental, Investigational

Phase 3

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Methotrexate

Approved

Phase 3

1959-05-2, 59-05-2

4112 126941

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Mercaptopurine

Approved

Phase 3

50-44-2

667490

Prednisolone phosphate

Approved, Vet_approved

Phase 3

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 3

52-21-1

Asparaginase Escherichia coli

Approved, Investigational

Phase 3

9015-68-3

Prednisolone

Approved, Vet_approved

Phase 3

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 3

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 3

83-43-2

4159 6741

Pegaspargase

Approved, Investigational

Phase 3

130167-69-0

Hydrocortisone succinate

Approved

Phase 3

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 3

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 3

50-23-7

3640 5754

Triamcinolone

Approved, Vet_approved

Phase 3

124-94-7

31307

Picropodophyllin

Approved, Investigational

Phase 3

518-28-5, 477-47-4

10607 72435

Prednisone

Approved, Vet_approved

Phase 3

53-03-2

5865

Abatacept

Approved

Phase 3

332348-12-6

Benzocaine

Approved, Investigational

Phase 3

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 3

1401-55-4

16129878 16129778

Vedolizumab

Approved

Phase 3

943609-66-3

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 3

59-30-3

6037

Interventional clinical trials:

(show top 50) (show all 450)

#	Name	Status	NCT ID	Phase	Drugs
1	Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation	Unknown status	NCT02784561	Phase 4	Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd);Cytarabine(Actavis Italy S.p.A);Fludarabine (Bayer);granulocyte colony-stimulating factor (KirinKunpeng);rabbit ATG（Sanofi/Genzyme）
2	Treatment Plan for Hematologic Malignancies Using Intravenous Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide to Examine Results, Success and Side Effects of Treatment With Chemotherapy Only, as a Preparative Therapy for Patients With Cord Blood Transplants	Unknown status	NCT01339988	Phase 4	Busulfan/Cyclophosphamide
3	An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy and Safety of Rasburicase (Fasturtec) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin¿s Lymphoma and Acute Leukemia	Completed	NCT04349306	Phase 4	RASBURICASE SR29142
4	Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever in Pediatric Acute Leukemia: Review of Temperature and Absolute Neutrophil	Completed	NCT04187755	Phase 4	Ceftazidime Injection;Cefepime Injection
5	Clinical Study of rATG Individualized Administration for Prevention of GVHD and Maintenance of GVL in Haploidentical Hematopoietic Stem Cell Transplantation.	Recruiting	NCT05634915	Phase 4	Individual ATG;ATG
6	Flumatinib Versus Imatinib Combined With Multiagent Chemotherapy for Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: A Prospective, Open-label，Randomized，Multi-center Clinical Trial	Recruiting	NCT05071482	Phase 4	Flumatinib;Imatinib
7	Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia in Patients With Acute Leukemia Receiving Chemotherapy	Unknown status	NCT02241031	Phase 2, Phase 3	thrombopoietin (TPO) and interleukin-11
8	Hypomethylating Agents + Donor Lymphocyte Infusion vs Donor Lymphocyte Infusion Preemptive Therapy Based on Minimal Residual Disease for Acute Leukemia Undergoing Allogenetic Hematopoietic Stem Cell Transplantation	Unknown status	NCT03662087	Phase 2, Phase 3
9	Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Unknown status	NCT03596892	Phase 2, Phase 3	Decitabine;Busulfan (BU);Cyclophosphamide (CY)
10	A Prospective, Multicenter Randomized Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in Children and Young Adults (<35 Years) With Acute Leukemia Remission	Unknown status	NCT01067300	Phase 3
11	A Phase I-II Pilot Clinical Trial of Safety and Efficacy of Personalized Targeted Preparative Regimen With Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation and Posttransplant Donor T- Cells Infusion in Children With Chemoresistаnt Acute Leukemia.	Unknown status	NCT04000698	Phase 3	Preparative regimen
12	Randomized Multicenter Trial of Two Transfusion Strategies for Patient Receiving Chemotherapy for Acute Leukemia or Hematopoietic Stem Cells With Medico-economic Evaluation of Cost Minimization.	Unknown status	NCT02461264	Phase 3	Single red blood packed cells Transfusion;Two packed red blood cells Transfusion
13	Oral Voriconazole vs IV Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction:A Prospective, Randomized, Clinical Trial.	Unknown status	NCT00624143	Phase 3	ORAL VORICONAZOLE and IV Amphotericin B
14	Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial	Unknown status	NCT01516580	Phase 3	Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
15	Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation	Unknown status	NCT01800643	Phase 2, Phase 3
16	Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study	Completed	NCT00678275	Phase 3	ATG FRESENIUS (Anti-Lymphocyte-Globulin)
17	A Phase III, Randomized, Multicentre Trial Comparing Allogeneic Filgrastim Mobilised Peripheral Blood Progenitor Cell Transplantation (PBPCT) With Allogeneic Bone Marrow Transplantation (BMT) in Patients With Acute Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome	Completed	NCT01020175	Phase 3
18	Clofarabine, Cyclophosfamide, And Etoposide For The Treatment Of Relapsed Or Resistant Acute Leukemia In Pediatric Patients	Completed	NCT01385891	Phase 2, Phase 3	Clofarabine VP 16 ciclophospahamide
19	A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)	Completed	NCT01371656	Phase 3	levofloxacin
20	A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301; Progress II)	Completed	NCT02345850	Phase 3	Cyclophosphamide;Tacrolimus;Methotrexate
21	Evaluation of Safety and Efficacy of Nalbuphine Versus Morphine Patient Controlled Analgesia (PCA) for Mucositis Pain in Pediatric Patients. A Prospective Randomized Double Blinded Clinical Trial	Completed	NCT03825887	Phase 3	Nalbuphine;Morphine
22	A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS	Completed	NCT00002534	Phase 3	cyclophosphamide;cytarabine;methylprednisolone;thiotepa
23	A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft	Recruiting	NCT05316701	Phase 3
24	Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3 Negative Acute Leukemia	Recruiting	NCT04674345	Phase 2, Phase 3	Sorafenib
25	Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia Patients Undergoing HSCT	Recruiting	NCT03799224	Phase 2, Phase 3	Decitabine;mBU/CY and ATG;mBU/CY
26	Comparing Post-Transplant Cyclophosphamide With Calcineurin Inhibitors as A GVHD Prophylaxis to Standard Care of Methotrexate and Calcineurin Inhibitors for Acute Leukemia Incorporating Patient Pharmacogenomics Profiling	Recruiting	NCT04314219	Phase 3	Cyclophosphamide 50mg;Methotrexate
27	Decitabine Plus mBU/CY for High Risk Acute Leukemia With Minimal Residual Disease Pre-HSCT	Recruiting	NCT03793517	Phase 2, Phase 3	Decitabine;mBU/CY and ATG;mBU/CY
28	A Phase III, Randomized, Clinical Trial Comparing Two Diets in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT) or Remission Induction Chemotherapy for Acute Leukemia and Myelodysplastic Syndrome (UF-BMT-LDND-101)	Recruiting	NCT03016130	Phase 3
29	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy	Recruiting	NCT03959085	Phase 3	Calaspargase Pegol-mknl;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine Sulfate
30	A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia or Myelodysplastic Syndrome (MDS)	Recruiting	NCT05457556	Phase 3	Busulfan;Cyclophosphamide;Fludarabine;Melphalan;Methotrexate;Mycophenolate Mofetil;Tacrolimus;Thiotepa
31	Evaluation of a Donor Testing Kit for the Prediction of Acute GVHD in Patient Receiving a Peripheral Blood Stem Cells Allograft- Predictor 2	Recruiting	NCT03887156	Phase 2, Phase 3
32	International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones	Recruiting	NCT03007147	Phase 3	Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Dexrazoxane Hydrochloride;Doxorubicin;Etoposide;Ifosfamide;Imatinib Mesylate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisolone;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
33	A Phase 3, Open Label, Single Arm, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients	Recruiting	NCT04446130	Phase 3	Decitabine combined with HAAG Regimen
34	A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies	Active, not recruiting	NCT02730299	Phase 3	NiCord® (omidubicel)
35	Extension of a Phase III Randomized Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen-HaploMUD-RIC-01	Active, not recruiting	NCT03595800	Phase 3
36	A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)	Active, not recruiting	NCT03959241	Phase 3	Tacrolimus;Methotrexate;Mycophenolate Mofetil;Cyclophosphamide
37	A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807)	Active, not recruiting	NCT00557193	Phase 3	Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Etoposide;Lestaurtinib;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
38	Interfant-21 International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.	Not yet recruiting	NCT05327894	Phase 3	Blinatumomab
39	A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy	Not yet recruiting	NCT05602194	Phase 3	Calaspargase Pegol-mknl;Pegaspargase
40	Prospective Pilot Study of the Clinical Efficacy and Safety of the Method for Preventing a Graft-versus-host Disease Through the Agency of Using the Combination of Post-transplantation Cyclophosphamide With Abatacept, Vedolizumab and Calcineurin Inhibitor at Children and Young Adults With Hemoblastosis After Hematopoietic Stem Cell Transplantation From an Unrelated or Haploidentic Donor	Not yet recruiting	NCT05515029	Phase 3
41	A Phase 3 Randomised Double-Blinded Placebo-Controlled Study of Use of GnRHa During Chemotherapy for Fertility Protection of Young Women and Teenagers With Cancer	Not yet recruiting	NCT05328258	Phase 3	Triptorelin Embonate;Sodium Chloride solution 0.9%
42	TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia	Terminated	NCT00914628	Phase 3
43	Allogeneic Stem Cell Transplantation Using Mylotarg (CMA-676) Plus Nonmyeloablative Chemotherapy in Older or Medically Infirm Patients With High-Risk Acute Leukemia (ALL), Chronic Myelogenous Leukemia (CML) or Myelodysplastic Syndrome (MDS)	Terminated	NCT00038805	Phase 2, Phase 3	Mylotarg
44	Effects of Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia	Withdrawn	NCT00943709	Phase 3	therapeutic insulin
45	Clinical Study of Genetically Modified Dendritic Cells Combining to Cytokine-Induced Killer Cells for Patients With Relapse Acute Leukemia After Allo-HSCT	Unknown status	NCT01956630	Phase 1, Phase 2
46	Multiple Consolidation Chemotherapy and DLI Prevent Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant and Achieving Complete Remission After Induction Chemotherapy and DLI	Unknown status	NCT03297528	Phase 2	donor lymphocyte infusion
47	Chemo Sensitization Before Hematopoietic Stem Cell Transplantation With a CXCR4 Antagonist in Patients With Acute Leukemia in Complete Remission: Pilot Study	Unknown status	NCT02605460	Phase 2	Busulfan;Cyclophosphamide;CXCR4 Antagonist
48	Phase I/II Study of PR104 in Subjects With Refractory/Relapsed Acute Leukemia Using Adaptive Dose Selection	Unknown status	NCT01037556	Phase 1, Phase 2	PR104
49	Allo-allo Tandem Matched Stem Cell Transplantation (AATT) for the Treatment of Patients With Refractory Acute Leukemia; a Feasibility Phase I/II Study	Unknown status	NCT00984412	Phase 1, Phase 2
50	Phase 2 Double-blind, Randomized, Placebo Controlled Clinical Trial for the Prevention of Oral Mucositis Using Sub-microbial Doses of Doxycycline Hyclate in Patients With Acute Leukemia Receiving Induction Chemotherapy	Unknown status	NCT01087476	Phase 2	Doxycycline hyclate

Search NIH Clinical Center for Acute Leukemia

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Acute Leukemia cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Acute Leukemia:

Promostem, mesenchymal stem cells for treatment of graft-versus-host disease

Sources

Genetic Tests for Acute Leukemia

Genetic tests related to Acute Leukemia:

#	Genetic test	Affiliating Genes
1	Acute Leukemia ²⁸

Sources

Anatomical Context for Acute Leukemia

Organs/tissues related to Acute Leukemia:

MalaCards : Bone Marrow, Myeloid, T Cells, Bone, Nk Cells, Liver, Neutrophil

Sources

Publications for Acute Leukemia

Articles related to Acute Leukemia:

(show top 50) (show all 20677)

#	Title	Authors	PMID	Year
1	Bench to bedside targeting of FLT3 in acute leukemia. ⁵³ ⁶²	Pratz KW...Levis MJ	20370649	2010
2	A role for PKR in hematologic malignancies. ⁵³ ⁶²	Blalock WL...Cocco L	20232306	2010
3	Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. ⁵³ ⁶²	Heesch S...Baldus CD	20435628	2010
4	Targeting CREB for cancer therapy: friend or foe. ⁵³ ⁶²	Xiao X...Sakamoto KM	20370681	2010
5	Adenovirus-mediated stem cell leukemia gene transfer induces rescue of interstitial cells of Cajal in ICC-loss mice. ⁵³ ⁶²	Li F...Liu B	20165856	2010
6	Clinical correlation of circulating heat shock protein 70 in acute leukemia. ⁵³ ⁶²	Yeh CH...Albitar M	19800118	2010
7	Methylenetetrahydrofolate reductase gene polymorphisms: association with risk for pediatric acute lymphoblastic leukemia in north Indians. ⁵³ ⁶²	Sood S...Marwaha RK	20367562	2010
8	RUNX1/core binding factor A2 regulates platelet 12-lipoxygenase gene (ALOX12): studies in human RUNX1 haplodeficiency. ⁵³ ⁶²	Kaur G...Rao AK	20181616	2010
9	Complex and cryptic chromosomal rearrangements involving the MLL gene in acute leukemia: a study of 7 patients and review of the literature. ⁵³ ⁶²	De Braekeleer E...De Braekeleer M	20206559	2010
10	The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0. ⁵³ ⁶²	Suzuki R...Naoe T	20111912	2010
11	[Expression of CREB/Bcl-2 in bone marrow mononuclear cells of children with acute leukemia]. ⁵³ ⁶²	Wen C...Wan WQ	20350424	2010
12	Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. ⁵³ ⁶²	Liu T...Schwaller J	20072157	2010
13	Retroviral insertional mutagenesis identifies Zeb2 activation as a novel leukemogenic collaborating event in CALM-AF10 transgenic mice. ⁵³ ⁶²	Caudell D...Aplan PD	20007546	2010
14	Droplet-based gene expression analysis using a device with magnetic force-based-droplet-handling system. ⁵³ ⁶²	Okochi M...Honda H	20129107	2010
15	[FLT3 gene mutation and its prognostic implication in patients with acute leukemia.]. ⁵³ ⁶²	Sino-US Shanghai Leukemia Cooperative Group	20302766	2010
16	Proleukemic RUNX1 and CBFbeta mutations in the pathogenesis of acute leukemia. ⁵³ ⁶²	Engel ME...Hiebert SW	20306249	2010
17	PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. ⁵³ ⁶²	Rivera-Del Valle N...Chandra J	20145726	2010
18	Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia. ⁵³ ⁶²	Steiner M...Austrian Berlin-Frankfurt-Munster Study Group	19935430	2010
19	Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. ⁵³ ⁶²	Busse A...Keilholz U	19404640	2009
20	[Clinical significance of detecting serum erythropoietin in patients with leukemia]. ⁵³ ⁶²	Su N...Liu J	19923094	2009
21	Discrepant immunophenotypic characteristics between the lymph node and bone marrow in two mixed-phenotype acute leukemia patients. ⁵³ ⁶²	Song MJ...Kim SH	19893347	2009
22	PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation. ⁵³ ⁶²	Blalock WL...Martelli AM	19507191	2009
23	Outcomes of CAG regimen for refractory biphenotypic acute leukemia patients. ⁵³ ⁶²	He GS...Han Y	19848320	2009
24	Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding. ⁵³ ⁶²	Le H...Vaughan AT	19530238	2009
25	New insights to the MLL recombinome of acute leukemias. ⁵³ ⁶²	Meyer C...Marschalek R	19262598	2009
26	Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. ⁵³ ⁶²	Nowakowska-Kopera A...Skotnicki AB	19811333	2009
27	ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. ⁵³ ⁶²	Svirnovski AI...Fedasenka UU	19635183	2009
28	Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity. ⁵³ ⁶²	Rytting ME...Albitar M	19605811	2009
29	Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. ⁵³ ⁶²	Ren M...Cowell JK	19506298	2009
30	[Studies on the mutation and polymorphism of the TPMT gene in Chinese children with acute leukemia]. ⁵³ ⁶²	Chen XW...Zhang M	20017316	2009
31	Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population. ⁵³ ⁶²	Xu XQ...Qiu HY	19454497	2009
32	GATA-1 and GATA-2 binding to 3' enhancer of WT1 gene is essential for its transcription in acute leukemia and solid tumor cell lines. ⁵³ ⁶²	Furuhata A...Murate T	19212333	2009
33	Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. ⁵³ ⁶²	Xu Z...Wang J	19250671	2009
34	Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3. ⁵³ ⁶²	Fukuda S...Pelus LM	19411632	2009
35	DNA damage response as a biomarker in treatment of leukemias. ⁵³ ⁶²	Halicka HD...Darzynkiewicz Z	19411853	2009
36	Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. ⁵³ ⁶²	Fiskus W...Bhalla KN	19279403	2009
37	High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. ⁵³ ⁶²	Preudhomme C...Sobol H	19357396	2009
38	Detection of myeloperoxidase activity in primary leukemic cells by an enhanced chemiluminescent assay for differentiation between acute lymphoblastic and non-lymphoblastic leukemia. ⁵³ ⁶²	Tan S...Chen F	19298796	2009
39	[IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia]. ⁵³ ⁶²	Qian SX...Qiu HX	19379589	2009
40	[Myeloproliferative diseases caused by JAK2 mutation]. ⁵³ ⁶²	Nagata K...Shimoda K	19489438	2009
41	Overexpression of an isoform of AML1 in acute leukemia and its potential role in leukemogenesis. ⁵³ ⁶²	Liu X...Wang J	19151769	2009
42	HOXA9 is required for survival in human MLL-rearranged acute leukemias. ⁵³ ⁶²	Faber J...Armstrong SA	19056693	2009
43	Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. ⁵³ ⁶²	Fakler M...Fulda S	19036706	2009
44	Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. ⁵³ ⁶²	Kwok C...So CW	19202074	2009
45	Maternal acute lymphoctic leukemia with rearrangement of the mixed lineage leukemia gene occurring during pregnancy. ⁵³ ⁶²	Aljurf M...Chaudhri N	20139053	2009
46	Expression of lineage markers using real-time quantitative polymerase chain reaction (RT-qPCR) in normal and in leukemia bone marrow. ⁵³ ⁶²	Saussoy P...Latinne D	19327122	2009
47	A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. ⁵³ ⁶²	Yin B...Largaespada DA	18948576	2009
48	The role of myeloid growth factors in acute leukemia. ⁵³ ⁶²	Wadleigh M...Stone RM	19176208	2009
49	New thrombopoietic growth factors. ⁵³ ⁶²	Kuter DJ	19778863	2009
50	Panhandle PCR approaches to cloning MLL genomic breakpoint junctions and fusion transcript sequences. ⁵³ ⁶²	Robinson BW...Felix CA	19277575	2009

Sources

Genes for Acute Leukemia

Genes related to Acute Leukemia (0 elite genes):

(show top 50) (show all 80)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	KMT2A	Lysine Methyltransferase 2A	Protein Coding	36.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	8443374 11069023 8824725 (more) 9447829 17284365 9029018 10557043 12472570 7658717 16983345 9230194 11167824 8016145 16383239 7529550 1423625 7885037 15755504 15160920 9010221 8703835 8298125 8378328 15269783 8709635 9247308 20206559 9539779 12957285 19074864 8329709 8616868 9353299 15323147 15322560 12860012 11522623 11510203 11433529 11289128 10583275 9760153 18224408 16433901 15626757 14575001 11527155 11477655 10822761 9844603 9539705 9292512 8558942 7675546 19262598 18474298 17164354 16511515 16843108 16085566 8134107 8282816 8361504 17854664 17726105 16857431 16105754 15464450 12368154 12165445 10679814 10457404 10381524 9592986 10825008 10706136 10374852 8108133 19277575 17942707 16357144 16424875 15815718 12835743 10233389 8616778 8044771 8506328 20139053 19530238 8934551 8640793 7761425 7949133 20080465 17957188 17854671 16158928 14704031
2	FLT3	Fms Related Receptor Tyrosine Kinase 3	Protein Coding	34.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	17584026 15778081 17387224 (more) 18925699 20302766 20515557 12357354 15996732 17233551 19052976 8677746 20072157 1384791 10803532 16757428 12796379 16800917 16321848 16185475 10373018 19075657 16557239 12836614 15374944 16025155 15618475 8562934 20425341 17708815 17943971 8637232 20370649 15950498 18977066 15150124 16418499 17584149
3	ETV6	ETS Variant Transcription Factor 6	Protein Coding	32.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	11343784 8808688 12823350 (more) 7780150 9529134 12555218 9060558 11439334
4	WT1	WT1 Transcription Factor	Protein Coding	32.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	7949179 10100271 16129044 (more) 7596170 17803653 19212333 19662212 10480287 18161786 12215007 12835718 14510942 16876863 10422290 10921096 12357365 15363132 9222290 15730716 9484784 19811333 7643450 15534117 8639907 8630376 17690705 15907324 12080641 10529509 9531607 16341043 16471322 12971856 12200377 11807803 8943879 20129107 15339675 12411055 12215009 10607714 9609529 9052749 15920488 11852808 11296223 20013787 19404640 18443273 12837194 12613515 11602325 10378895 15223632 11014901 12750711 9001425 10674900 20435628 10360378
5	BAALC	BAALC Binder Of MAP3K1 And KLF4	Protein Coding	32.37	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name Proteins (show sections)
6	RUNX1	RUNX Family Transcription Factor 1	Protein Coding	32.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	17920312 16575471 20306249 (more) 17532767 17968322 8613429 10482986 17011991 19151769 10684580 20080465 20007546 10717473 12771199 15156187 15950498 16247465 20181616 8395311 8049440 12604126 15988004 16803898 11566347 12555067 11328817 10594034 19357396 18224409 7780155 9031072 10825008 11023523
7	JAK2	Janus Kinase 2	Protein Coding	30.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	18394555 18618714 15805263 (more) 16037387 16557239 18297515 17077140 17068151 18024602 18230964 19489438
8	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	30.34	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	9407735 9658721 10229319 (more) 10739002 8605274 12562262 18977066 12836614 20165856 7529077 1371882 18787634 8127154 12194988 18337231
9	MTHFR	Methylenetetrahydrofolate Reductase	Protein Coding	28.25	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Summaries (show sections)	17071478 17071465 11340609 (more) 11274424 20367562 12827651 17339179 12672676
10	CEBPA	CCAAT Enhancer Binding Protein Alpha	Protein Coding	28.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	12351377
11	STMN1	Stathmin 1	Protein Coding	26.96	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Expressions (show sections)	1917919 1401087 8412315 (more) 9324290 7925472 1930203 8125092
12	CREBBP	CREB Binding Protein	Protein Coding	26.9	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	10469454 10706136
13	PBX1	PBX Homeobox 1	Protein Coding	26.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	9205098
14	AFF1	ALF Transcription Elongation Factor 1	Protein Coding	25.64	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8353274 7698025 11527155 (more) 8378328 1423625 15269783
15	PAX5	Paired Box 5	Protein Coding	25.3	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	14676435 15492262
16	GSTM1	Glutathione S-Transferase Mu 1	Protein Coding	25.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Functions (show sections)	15862746 17581325 18610829 (more) 16676594 15738600 16493615 12827651
17	CSF3	Colony Stimulating Factor 3	Protein Coding	24.89	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8691565 7531394 16858272 (more) 1714757 10942233 9644302 10897214 8637222 11290617 10731945 12752636 9590144 18020493 8624474 9387641 7689127 8588087 10217192 10358698 11869937 8528046 1534271 1709294 19379589 16928319 17563736 16988532 11979751 11486703 8721901 19749982 16777623 11736947 11399510 11105617 11091203 9570678 8656684 19848320 17128529 1697646 17631182 16192477 10657885 7535728 7526087 1372766 1707827 15850828 15461640 14691124 11293503 16295383 14959860 9447843 8608239 7525188 7525857 16080844 8616084 17526862 12393493 14675405 14642178
18	DNTT	DNA Nucleotidylexotransferase	Protein Coding	24.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7723388 1338518 18426728 (more) 7524307 10233410 11131924 19687594 7639197 10655992 7962655 8853033 7496347 1299244 15205205 7654005 8220154 1913454
19	TCF3	Transcription Factor 3	Protein Coding	24.26	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
20	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	24.14	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	12194988
21	ANPEP	Alanyl Aminopeptidase, Membrane	Protein Coding	23.95	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12562262 11241503 8023515 (more) 1493908 10229319 8624374
22	MPO	Myeloperoxidase	Protein Coding	23.9	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19935430 9725460 8396697 (more) 17479404 8386105 7493141 1666891 9217186 8579056 15624329 9704614 1311196 1333591 7719239 10233410 10986389 12562262 15786701 9140287 2173803 19327122 19298796 8167554 7944272 8035623 8023515 8118606 8220154 7962655 10655992 8624374 9859768 7496347 8291896 8388970 8383541 10889907 8155836 1977771 8853033 12513830 11340609 10359066 9766845 9479874 8659452 8237269 8501986 16298822 16893519 17325954 19605811 19893347 1913454 1331562
23	ZNF384	Zinc Finger Protein 384	Protein Coding	23.74	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Summaries (show sections)
24	CD34	CD34 Molecule	Protein Coding	23.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19454497 9001869 1712541 (more) 7505888 7526089 10916777 8635059 9658721 11489469
25	TAL1	TAL BHLH Transcription Factor 1, Erythroid Differentiation Factor	Protein Coding	23.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10049045 1311214 15917481 (more) 8142619 9211539 18495761 16298389 8058326
26	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	23.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8477061 16086884 15512810 (more) 17538395 16614510 10897123 9150348 1380280 9886170 1859877 11877057 7694687 19291917 9742628 10444168 12917035 8731823 12028995 9439046 10920991 8556928 1283551 19862976 9408959 7808005 14526424 8704189 1974821 16138358 15266171 9479874 8535665 7536492 8639853 10971394 10500792 10500786 10500776 10198619 8726405 8656697 8574159 7727868 16109615 12960118 11036680 7895588 7993790 19635183 17301357 11798628 11197207 7622426 8102639 8630412 7528566 7914424 8100604 16799654 15014037 11697502 9868094 1353871 17493328 15854288 9772402 8118816 15363121 8097038 7896208 8075575 9110459 10374270
27	IL3	Interleukin 3	Protein Coding	23.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1766257 8624474 9891868 (more) 2403822 2323674 2090254 7689127 2048564 1635377 8449858 14752873 10721770 2312610 8881103 7515617 8422455 9414269 9067570 8211215 9466481 10496036
28	MLLT3	MLLT3 Super Elongation Complex Subunit	Protein Coding	23.16	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15269783
29	DNMT3A	DNA Methyltransferase 3 Alpha	Protein Coding	23.08	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
30	MLLT10	MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor	Protein Coding	22.95	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11423977
31	HOXA9	Homeobox A9	Protein Coding	22.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16102826 16518848 18337761 (more) 15160920 19056693
32	SETD2	SET Domain Containing 2, Histone Lysine Methyltransferase	Protein Coding	22.3	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
33	CD7	CD7 Molecule	Protein Coding	22.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1701841
34	MLLT1	MLLT1 Super Elongation Complex Subunit	Protein Coding	22.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16990786
35	GATA1	GATA Binding Protein 1	Protein Coding	21.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14636651 8035609 7780155 (more) 10360378 16631466 7808006 14701703 7579412 9808054 16998319 19212333 17913678 12560215 16960339 20007546 15198727
36	IL3RA	Interleukin 3 Receptor Subunit Alpha	Protein Coding	21.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11726317 12950240 11021753 (more) 14671644 15020268
37	CDKN2B	Cyclin Dependent Kinase Inhibitor 2B	Protein Coding	21.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9447829 11876990 11413509 (more) 11721412 10634644 8616035 12150726 10073286 15755508 11721363 15737564 12600181 9817058 15854288
38	CD22	CD22 Molecule	Protein Coding	21.55	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8501986
39	CSF2	Colony Stimulating Factor 2	Protein Coding	21.43	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1697646 1714757 8616084 (more) 9414269 17252021 19176208 17958545 9455573 8624474 12357348 15541469 17631182 18020493 11399510
40	SETBP1	SET Binding Protein 1	Protein Coding	21.06	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)
41	EIF2AK2	Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2	Protein Coding	21.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications localization (show sections)	19507191 14961569 20232306
42	NUP98	Nucleoporin 98 And 96 Precursor	Protein Coding	20.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11841413 16419055 16651408 (more) 12874791
43	IL2	Interleukin 2	Protein Coding	20.77	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8355048 2375921 1988139 (more) 1751372 7787749 10770624 10705305 1434844 9869198 15892271 8608212 15541469 8169977 9167045 8642865 2202476 9922080 1640729 9116606 8640841 1766257 17500047 9457394 9250817 8733689 1578937 9180298 8562379 2043762 10414450 7526078 2036661 2092277 15646345 9179281 16249392 10546793 1635377
44	BCR	BCR Activator Of RhoGEF And GTPase	Protein Coding	20.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1993310 1545509 8020705 (more) 8251902 1985699 1317490 2067074 8435337 2094324 7901455
45	ABCC1	ATP Binding Cassette Subfamily C Member 1	Protein Coding	20.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12658928 17538395 16614510 (more) 18711657 11798719 19291917 7808005 11877057 16086885 17493328 19065772 9868094 11697502 19468272 11798628 11940320 16109615 10500792 17671794 14575539 7528566 15014037
46	PRAME	PRAME Nuclear Receptor Transcriptional Regulator	Protein Coding	20.65	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16860864 16044453 9753074 (more) 12620290
47	MEIS1	Meis Homeobox 1	Protein Coding	20.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10996203 15160920
48	MVP	Major Vault Protein	Protein Coding	20.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16045016 17538395 11798719 (more) 16086885 16614510 11697502 11876952 11940320 10971394 14723828 14575539 8630412
49	THPO	Thrombopoietin	Protein Coding	20.22	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9760150 16801066 11601235 (more) 11678339 10742383 8888496 9529122 18819233 19778863 12879435
50	GATA2	GATA Binding Protein 2	Protein Coding	20.2	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8035609 7780155 7808006 (more) 14701703 7579412 19212333 9479874 11877047

Sources

Variations for Acute Leukemia

Sources

Expression for Acute Leukemia

Search GEO for disease gene expression data for Acute Leukemia.

Sources

Pathways for Acute Leukemia

Pathways related to Acute Leukemia according to GeneCards Suite gene sharing:

(show all 15)

#	Super pathways	Score	Top Affiliating Genes
1	Nervous system development ⁶⁶ Show member pathways Axon guidance ⁶⁶ Developmental Biology ⁶⁶	13.51	WT1 TCF3 RUNX1 PBX1 KRAS KMT2A
2	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.7	KRAS KIT JAK2 FLT3 CSF3
3	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.52	FLT3 JAK2 KIT KRAS STMN1
4	Development EPO-induced Jak-STAT pathway ²² Show member pathways EPO receptor signaling ⁷⁴ Signaling events mediated by Stem cell factor receptor (c-Kit) ⁶¹	11.78	KIT JAK2 CREBBP
5	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.76	KIT FLT3 CSF3
6	Gastrin signaling pathway ⁷⁴	11.74	KRAS KIT JAK2
7	NF-kappaB Signaling ³	11.68	TCF3 RUNX1 PBX1 PAX5 KIT JAK2
8	Signaling by SCF-KIT ⁶⁶ Show member pathways Regulation of KIT signaling ⁶⁶ Signaling by KIT in disease ⁶⁶ Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants ⁶⁶	11.65	KRAS KIT JAK2
9	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.44	KRAS KIT FLT3
10	C-MYB transcription factor network ⁶¹	11.26	PAX5 KIT GSTM1 CREBBP CEBPA
11	Signaling by CSF3 (G-CSF) ⁶⁶ Show member pathways Inactivation of CSF3 (G-CSF) signaling ⁶⁶	11.24	KRAS JAK2 CSF3
12	Notch-mediated HES/HEY network ⁶¹	11.09	TCF3 JAK2 CREBBP
13	Hematopoietic stem cell gene regulation by GABP alpha/beta complex ⁷⁴	10.63	FLT3 ETV6 CREBBP
14	RUNX1 regulates transcription of genes involved in differentiation of myeloid cells ⁶⁶ Show member pathways RUNX2 regulates genes involved in differentiation of myeloid cells ⁶⁶	10.5	RUNX1 CREBBP
15	RUNX1 regulates transcription of genes involved in BCR signaling ⁶⁶ Show member pathways RUNX1 regulates transcription of genes involved in interleukin signaling ⁶⁶	10.47	RUNX1 PAX5

Sources

GO Terms for Acute Leukemia

Biological processes related to Acute Leukemia according to GeneCards Suite gene sharing:

(show all 14)

#	Name	GO ID	Score	Top Affiliating Genes
1	cell differentiation	GO:0030154	10.19	TCF3 STMN1 PBX1 PAX5 JAK2 FLT3
2	regulation of DNA-templated transcription	GO:0006355	10.07	WT1 TCF3 RUNX1 PBX1 PAX5 KMT2A
3	positive regulation of DNA-binding transcription factor activity	GO:0051091	10.03	TCF3 KIT JAK2 CSF3
4	B cell differentiation	GO:0030183	10.01	TCF3 PAX5 KIT FLT3
5	visual learning	GO:0008542	9.93	KIT KMT2A KRAS
6	regulation of cell population proliferation	GO:0042127	9.92	PBX1 KIT FLT3 CEBPA
7	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.92	CSF3 FLT3 JAK2 KIT
8	hematopoietic stem cell proliferation	GO:0071425	9.85	RUNX1 ETV6 CEBPA
9	myeloid progenitor cell differentiation	GO:0002318	9.78	FLT3 KIT
10	positive regulation of transcription by RNA polymerase II	GO:0045944	9.66	WT1 TCF3 RUNX1 PBX1 PAX5 KMT2A
11	cytokine-mediated signaling pathway	GO:0019221	9.65	CEBPA CSF3 FLT3 JAK2 KIT
12	embryonic hemopoiesis	GO:0035162	9.63	PBX1 KMT2A KIT
13	positive regulation of response to stimulus	GO:0048584	9.51	KIT FLT3
14	positive regulation of protein modification process	GO:0031401	9.49	KIT FLT3

Molecular functions related to Acute Leukemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transcription cis-regulatory region binding	GO:0000976	9.81	WT1 TCF3 RUNX1 PBX1 CEBPA
2	DNA-binding transcription factor binding	GO:0140297	9.8	TCF3 PBX1 CREBBP CEBPA
3	DNA-binding transcription factor activity	GO:0003700	9.73	CEBPA ETV6 PAX5 PBX1 RUNX1 TCF3
4	DNA-binding transcription activator activity, RNA polymerase II-specific	GO:0001228	9.47	WT1 TCF3 RUNX1 PBX1 PAX5 ETV6